1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Europe Human Papillomavirus (HPV) Vaccine Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Europe Human Papillomavirus (HPV) Vaccine Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Europe Human Papillomavirus (HPV) Vaccine Market Regional Analysis
6.2 Europe Human Papillomavirus (HPV) Vaccine Market Revenue 2020-2028 (US$ Million)
6.3 Europe Human Papillomavirus (HPV) Vaccine Market Forecast Analysis
7. Europe Human Papillomavirus (HPV) Vaccine Market Analysis – by Type
7.1 9-valent HPV Vaccine
- 7.1.1 Overview
- 7.1.2 9-valent HPV Vaccine: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)
7.2 Quadrivalent HPV Vaccine
- 7.2.1 Overview
- 7.2.2 Quadrivalent HPV Vaccine: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)
7.3 Bivalent HPV Vaccine
- 7.3.1 Overview
- 7.3.2 Bivalent HPV Vaccine: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)
8. Europe Human Papillomavirus (HPV) Vaccine Market Analysis – by Dosage
8.1 2 Dose and 3 Dose
- 8.1.1 Overview
- 8.1.2 2 Dose and 3 Dose: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)
9. Europe Human Papillomavirus (HPV) Vaccine Market Analysis – by Age
9.1 9 to 14 Years and 15 to 45 Years
- 9.1.1 Overview
- 9.1.2 9 to 14 Years and 15 to 45 Years: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)
10. Europe Human Papillomavirus (HPV) Vaccine Market Analysis – by Application
10.1 HPV-Attributable Cancer and Genital Warts
- 10.1.1 Overview
- 10.1.2 HPV-Attributable Cancer and Genital Warts: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)
11. Europe Human Papillomavirus (HPV) Vaccine Market – Europe Analysis
11.1 Overview
11.2 Europe
- 11.2.1 Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Key
Country, 2023 and 2028 (%)
- 11.2.1.1 Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and
Forecast Analysis – by Country
- 11.2.1.1 UK:
Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.1.1 UK: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
- 11.2.1.1.2 UK: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
- 11.2.1.1.3 UK: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
- 11.2.1.1.4 UK: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application
- 11.2.1.2 Germany:
Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.2.1 Germany: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
- 11.2.1.2.2 Germany: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
- 11.2.1.2.3 Germany: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
- 11.2.1.2.4 Germany: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application
- 11.2.1.3 France:
Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.3.1 France: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
- 11.2.1.3.2 France: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
- 11.2.1.3.3 France: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
- 11.2.1.3.4 France: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application
- 11.2.1.4 Russia:
Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.4.1 Russia: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
- 11.2.1.4.2 Russia: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
- 11.2.1.4.3 Russia: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
- 11.2.1.4.4 Russia: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application
- 11.2.1.5 Italy:
Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.5.1 Italy: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
- 11.2.1.5.2 Italy: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
- 11.2.1.5.3 Italy: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
- 11.2.1.5.4 Italy: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application
- 11.2.1.6 Rest of Europe:
Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.6.1 Rest of Europe: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
- 11.2.1.6.2 Rest of Europe: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
- 11.2.1.6.3 Rest of Europe: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
- 11.2.1.6.4 Rest of Europe: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 2A Pharma
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 ChengDu Institute of Biological Products Co., Ltd.
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 GlaxoSmithKline plc.
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Inovio Pharmaceuticals
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Merck & Co., Inc.
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 R-Pharm
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Sanofi
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Serum Institute of India Pvt. Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Vaccitech
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Walvax Biotechnology Co., Ltd.
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations
Get Free Sample For Europe Human Papillomavirus (HPV) Vaccine Market
